CancerDrs

Pancreatic Cancer clinical trials in Wisconsin

41 actively recruiting pancreatic cancer trials at 49 sites across Wisconsin.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care …

Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Wisconsin:
  • Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
  • Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
  • Aurora Saint Luke's South Shore — Cudahy, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Aurora Health Care Germantown Health Center — Germantown, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Wisconsin:
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Northwest Wisconsin Cancer Center — Ashland, Wisconsin
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
  • Essentia Health-Hayward Clinic — Hayward, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in Wisconsin:
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Northwest Wisconsin Cancer Center — Ashland, Wisconsin
  • Essentia Health-Hayward Clinic — Hayward, Wisconsin
  • Tamarack Health Hayward Medical Center — Hayward, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…

Sponsor: Pfizer
NCT ID: NCT06989437
Sites in Wisconsin:
  • Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Wisconsin:
  • Investigative Site US044 — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Wisconsin:
  • Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…

Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in Wisconsin:
  • Medical College of Wisconcin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcino…

Sponsor: Panbela Therapeutics, Inc.
NCT ID: NCT05254171
Sites in Wisconsin:
  • Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
  • Mercyhealth Hospital and Cancer Center - Janesville — Janesville, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Wisconsin:
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Northwest Wisconsin Cancer Center — Ashland, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Essentia Health-Hayward Clinic — Hayward, Wisconsin
  • Tamarack Health Hayward Medical Center — Hayward, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…

Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Wisconsin:
  • Ohio State University Telemedicine — Chippewa Falls, Wisconsin
  • Ohio State University Telemedicine — Green Bay, Wisconsin
  • Ohio State University Telemedicine — Madison, Wisconsin
  • Ohio State University-Telemedicine — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nod…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04172532
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Wisconsin:
  • UW Health Carbone Cancer Center — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07492680
Sites in Wisconsin:
  • Local Institution - 0134 — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in Wisconsin:
  • University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293) — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastroin…

Sponsor: GlaxoSmithKline
NCT ID: NCT06885034
Sites in Wisconsin:
  • GSK Investigational Site — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Wisconsin:
  • University of Wisconsin — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…

Sponsor: Phanes Therapeutics
NCT ID: NCT05482893
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…

Sponsor: Bayer
NCT ID: NCT06760819
Sites in Wisconsin:
  • UW Health Carbone Cancer Center — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…

Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Wisconsin:
  • University of Wisconsin — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…

Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in Wisconsin:
  • University of Wisconsin - Carbone Cancer Center — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT05245500
Sites in Wisconsin:
  • Local Institution - 108 — Milwaukee, Wisconsin
View on ClinicalTrials.gov →

Showing 25 of 41 trials with sites in Wisconsin. See all pancreatic cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01